Business
Peijia Medical Announces 2024 Annual Results
Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ended December 31, 2024 ("the Year") on March 25, 2025.
About this update from Peijia Medical Ltd.
[{"type":"text","content":"HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ended December 31, 2024 ("the Year") on March 25, 2025.","length":301,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Peijia Medical)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Peijia Medical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/e378995a692ee57ba72652d9104b47a3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pHSM1YpXq0qVN5y.SIsBsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e378995a692ee57ba72652d9104b47a3","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2166853/PEIJIA_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Financial Highlights","length":20,"tagName":"p"},{"type":"text","content":"During the Year, Peijia recorded operating revenue of RMB615.5 million, representing a 39.5% year-on-year increase. The revenue growth was driven by:","length":149,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued commercialization and expanded market share gains of transcatheter aortic valve replacement (TAVR) products across China;","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"The successful first-year nationwide launch of DCwire Micro Guidewire validated by positive user feedback and widespread market adoption;","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"Further market penetration of Syphonet Stent Retriever and Fastunnel Delivery Balloon Dilatation Catheter, supported by differentiated product design and innovative procedure techniques; and","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Sustained adoption of the Company's coil product under the volume-based procurement (VBP) initiatives, bolstered by reliable product quality and brand recognition.","length":167,"tagName":"p"}]}],"tagName":"ol","bulletedList":false,"length":640,"olType":"1"},{"type":"text","content":"Gross profit for the Year was RMB433.6 million, up 33.3% year-on-year. Benefiting from a diversified prod...